# Targeting the Glutaminolysis Pathway in Glaucoma-Associated Fibrosis

## TL;DR

This paper explores how targeting the glutaminolysis pathway could help treat fibrosis in glaucoma, a leading cause of irreversible vision loss.

## Contribution

The paper identifies glutaminolysis as a novel potential therapeutic target for glaucoma-associated fibrosis.

## Key findings

- Fibrosis in glaucoma involves ECM remodelling and metabolic reprogramming.
- Glutaminolysis is implicated in fibrosis and metabolic changes in cancer and other diseases.
- Current therapies targeting glutaminolysis suggest its potential for glaucoma treatment.

## Abstract

Glaucoma is a group of progressive optic neuropathies and the leading cause of irreversible vision loss worldwide. It is a chronic eye disease, and its major pathological features include fibrosis of the trabecular meshwork, Schlemm’s Canal and lamina cribrosa. Central to fibrosis is extracellular matrix (ECM) remodelling and metabolic reprogramming. Glutaminolysis is an alternative energy pathway that has previously been shown to be implicated in the metabolic reprogramming associated with cancer and other fibrotic diseases, facilitating ECM remodelling and cell proliferation. This paper reviews fibrosis, glutaminolysis in the setting of fibrosis, and fibrosis and glutaminolysis in the context of glaucoma. We review the evidence for fibrosis and metabolic reprogramming in oncology and systemic fibrotic diseases, which reveals a predilection for glutaminolysis. We review the current therapies that exist to target these pathways, and find glutaminolysis to be a potential target for future therapies in glaucoma.